The delivery platform and floating cannula are designed for delivering therapeutic agents to the spinal cord of patients with amyotrophic lateral sclerosis.

The device, which has been used in the recently completed Phase I ALS trial, has been demonstrated to be safe in 18 surgeries.

The terms of Neuralstem’s deal and license proceeds with Q Therapeutics have not been disclosed.

Neuralstem president and CEO Richard Garr said this is the beginning of a new paradigm in treating multiple indications for spinal cord diseases.

"Intraspinal delivery of therapeutics has long been thought to pose problems too difficult to overcome," Garr added.

"However, we have established compelling safety data in our first-in-human, 18-patient trial, and we expect to continue to license out the surgical devices to both industry and academia as they now begin to explore the possibilities our technology has enabled."